MCID: URT024
MIFTS: 23

Urethra Clear Cell Adenocarcinoma malady

Category: Cancer diseases

Aliases & Classifications for Urethra Clear Cell Adenocarcinoma

About this section

Aliases & Descriptions for Urethra Clear Cell Adenocarcinoma:

Name: Urethra Clear Cell Adenocarcinoma 11 13
Clear Cell Adenocarcinoma of the Urethra 11
 
Urethral Clear Cell Adenocarcinoma 68

Classifications:



External Ids:

Disease Ontology11 DOID:5307
NCIt45 C6172

Summaries for Urethra Clear Cell Adenocarcinoma

About this section
MalaCards based summary: Urethra Clear Cell Adenocarcinoma, also known as clear cell adenocarcinoma of the urethra, is related to adenocarcinoma and clear cell adenocarcinoma. An important gene associated with Urethra Clear Cell Adenocarcinoma is FNDC3B (Fibronectin Type III Domain Containing 3B), and among its related pathways is Hematopoietic Stem Cell Gene Regulation by GABP alpha/beta Complex. Related mouse phenotypes are homeostasis/metabolism and mortality/aging.

Related Diseases for Urethra Clear Cell Adenocarcinoma

About this section

Graphical network of the top 20 diseases related to Urethra Clear Cell Adenocarcinoma:



Diseases related to urethra clear cell adenocarcinoma

Symptoms & Phenotypes for Urethra Clear Cell Adenocarcinoma

About this section

MGI Mouse Phenotypes related to Urethra Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

41
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053767.1ALK, AMACR, APP, ARID2, ATM, FNDC3B
2MP:00107686.7ALK, AMACR, APP, ARID2, ATM, FNDC3B

Drugs & Therapeutics for Urethra Clear Cell Adenocarcinoma

About this section

Drugs for Urethra Clear Cell Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 24)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Fentanylapproved, illicit, investigational, vet_approvedPhase 3821437-38-73345
Synonyms:
1-Phenethyl-4-(N-phenylpropionamido)piperidine
1-Phenethyl-4-N-propionylanilinopiperidine
1-phenethyl-4-N-propionylanilinopiperidine
437-38-7
5-22-08-00049 (Beilstein Handbook Reference)
80832-90-2
990-73-8 (citrate)
AC1L1FQ2
Actiq
BIDD:GT0555
BRN 0494484
CHEBI:119915
CHEMBL596
CID3345
D00320
DB00813
Duragesic
Duragesic (TN)
Duragesic-100
Duragesic-12
Duragesic-25
Duragesic-50
Duragesic-75
Durogesic
EINECS 207-113-6
Fentanest
Fentanil
Fentanil [DCIT]
Fentanila
Fentanila [INN-Spanish]
Fentanilo
Fentanyl
Fentanyl (JAN/USAN/INN)
Fentanyl CII
Fentanyl [INN:BAN]
Fentanyl citrate
Fentanyl-100
Fentanyl-12
Fentanyl-25
 
Fentanyl-50
Fentanyl-75
Fentanylum
Fentanylum [INN-Latin]
HSDB 3329
IONSYS
JNS020QD
L001275
LS-124439
Matrifen
MolPort-003-847-369
N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-Phenethyl-4-piperidyl)propionanilide
N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide
N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide
N-(1-phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-phenethyl-4-piperidyl)propionanilide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropanamide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropionamide
N-Phenethyl-4-(N-propionylanilino)piperidine
N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenethyl-4-(N-propionylanilino)piperidine
N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide
NCGC00168252-01
Nasalfent
Oprea1_152073
Oprea1_207148
PDSP1_000860
PDSP2_000846
Pentanyl
Phentanyl
Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)- (9CI)
R 4263
Rapinyl
Sentonil
Sublimase
Sublimaze
UNII-UF599785JZ
fentanyl
2Liver ExtractsPhase 3, Phase 14067
3NarcoticsPhase 33646
4Adjuvants, AnesthesiaPhase 31674
5Peripheral Nervous System AgentsPhase 323689
6Central Nervous System DepressantsPhase 313403
7pancreatic polypeptidePhase 320
8AnalgesicsPhase 311733
9AnestheticsPhase 39596
10Analgesics, OpioidPhase 33238
11Anesthetics, GeneralPhase 32934
12Anesthetics, IntravenousPhase 32538
13ColaNutraceuticalPhase 3, Phase 11946
14
nivolumabapprovedPhase 1424946414-94-4
Synonyms:
BMS-936558
 
MDX-1106
ONO-4538
nivolumab
15
Docetaxelapproved, investigational, Approved May 1996Phase 11967114977-28-5148124, 9877265
Synonyms:
(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl (aR,bS)-b-[[(1,1-dimethylethoxy)carbonyl]amino]-a-hydroxybenzenepropanoate
(2alpha,5beta,7beta,10beta,13alpha)-4-(acetyloxy)-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7,10-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate
01885_FLUKA
114977-28-5
4-(Acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
4-(acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
AC-383
AC1L3WHJ
ANX-514
BIND-014
C11231
CHEBI:4672
CHEMBL92
CID148124
D07866
DB01248
Docetaxel
Docetaxel (INN)
Docetaxel anhydrous
Docetaxel, Trihydrate
EmDOC
 
HMS2089K08
InChI=1/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,5
MolPort-003-847-005
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-debenzoyl-N-Boc-10-deacetyl taxol
NSC-628503
PSMA-targeted docetaxel nanoparticle
RP-56976
SDP-014
TXL
Taxotere
Taxotere (TN)
Taxotere(R)
XRP-6976L
docetaxel
docetaxel 114977-28-5
nchembio.188-comp8
nchembio.2007.34-comp7
nchembio.573-comp11
nchembio853-comp8
16Antimitotic AgentsPhase 15657
17Immunosuppressive AgentsPhase 113086
18Anti-Bacterial AgentsPhase 111226
19Angiogenesis InhibitorsPhase 14257
20Anti-Infective AgentsPhase 122062
21Angiogenesis Modulating AgentsPhase 14185
22ImmunoglobulinsPhase 16394
23AntibodiesPhase 16394
24Antibodies, MonoclonalPhase 14039

Interventional clinical trials:

idNameStatusNCT IDPhase
1Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer PainCompletedNCT00538850Phase 3
2Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsNot yet recruitingNCT03170960Phase 1, Phase 2
3Thalidomide and Docetaxel in Treating Patients With Advanced CancerCompletedNCT00049296Phase 1
4Cabozantinib-s-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary TumorsRecruitingNCT02496208Phase 1
5Early Intervention vs. Standard Palliative Care in Improving End-of-Life Care in Advanced Cancer PatientsCompletedNCT00253383

Search NIH Clinical Center for Urethra Clear Cell Adenocarcinoma

Genetic Tests for Urethra Clear Cell Adenocarcinoma

About this section

Anatomical Context for Urethra Clear Cell Adenocarcinoma

About this section

Publications for Urethra Clear Cell Adenocarcinoma

About this section

Variations for Urethra Clear Cell Adenocarcinoma

About this section

Expression for genes affiliated with Urethra Clear Cell Adenocarcinoma

About this section
Search GEO for disease gene expression data for Urethra Clear Cell Adenocarcinoma.

Pathways for genes affiliated with Urethra Clear Cell Adenocarcinoma

About this section

Pathways related to Urethra Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

idSuper pathwaysScoreTop Affiliating Genes
19.6ATM, SMAD4

GO Terms for genes affiliated with Urethra Clear Cell Adenocarcinoma

About this section

Biological processes related to Urethra Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1female gonad developmentGO:000858510.3ATM, SMAD4
2ovarian follicle developmentGO:000154110.2ATM, SMAD4
3neuron apoptotic processGO:005140210.0APP, ATM
4branching involved in ureteric bud morphogenesisGO:00016589.9PAX8, SMAD4
5kidney developmentGO:00018229.6PAX8, SMAD4, UPK3A
6regulation of apoptotic processGO:00429818.8ALK, ATM, PAX8

Sources for Urethra Clear Cell Adenocarcinoma

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet